{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T04:20:29Z","timestamp":1649218829641},"reference-count":30,"publisher":"Japan Society for Clinical Immunology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.clin.Immun","Jpn. J. Clin. Immunol."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2177\/jsci.37.423","type":"journal-article","created":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T22:02:54Z","timestamp":1420581774000},"page":"423-429","source":"Crossref","is-referenced-by-count":0,"title":["Immunity against mycobacterium tuberculosis and risk of biological anti-rheumatic agents"],"prefix":"10.2177","volume":"37","author":[{"given":"Kozo","family":"YASUI","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"},{"name":"Department of Pediatrics, Hiroshima-City Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"972","reference":[{"key":"1","unstructured":"1) Keane, J., et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. <i>N Engl J Med<\/i>. <b>345<\/b>: 1098-1104, 2001."},{"key":"2","unstructured":"2) Askling, J., et al.: Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. <i>Arthritis Rheum<\/i>. <b>52<\/b>: 1986-1992, 2005."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Martin-Mola, E., Balsa, A.: Infectious complications of biologic agents. <i>Rheum Dis Clin North Am<\/i>. <b>35<\/b>: 183-199, 2009.","DOI":"10.1016\/j.rdc.2009.03.009"},{"key":"4","unstructured":"4) Peterson, J.R., et al.: Effect of tumor necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. <i>Ann Rheum Dis<\/i>. <b>62<\/b>: 1078-1082, 2003."},{"key":"5","unstructured":"5) Vassilopoulos, D., et al.: Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. <i>Ann Rheum Dis<\/i>. <b>69<\/b>: 1353-1355, 2010."},{"key":"6","unstructured":"6) Lan J.-L., et al.: Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumor necrosis factor alpha therapy. <i>Ann Rheum Dis<\/i>. <b>70<\/b>: 1719-1725, 2011."},{"key":"7","unstructured":"7) World Health Organaization: Global tuberculosis report 2013. WHO, Geneva, 2013. http:\/\/www.who.int\/tb\/publications\/global_report\/en\/"},{"key":"8","unstructured":"10) Kohwiwattanagun, J., et al.: Mycobacterial mammalian cell entry protein 1a (Mce1A)-mediated adherence enhances the chemokine production by A549 alveolar epithelial cells. <i>Microbiol Immunol<\/i>. <b>51<\/b>: 253-261, 2007."},{"key":"9","unstructured":"11) Kusunose, E., et al.: Superoxide dismutase from Mycobacterium tuberculosis. <i>J Biochem<\/i>. <b>80<\/b>: 1343-1352, 1976."},{"key":"10","doi-asserted-by":"crossref","unstructured":"13) Jozefowski, S., Marcinkiewicz, J.: Aggregates of denatured proteins stimulate nitric oxide and superoxide production in macrophages. <i>Inflamm Res<\/i>. <b>59<\/b>: 277-289, 2010.","DOI":"10.1007\/s00011-009-0096-5"},{"key":"11","unstructured":"14) Casbon, A.J., et al.: Effects of IFN-\u03b3 on intracellular trafficking and activity of macrophage NADPH oxidase flavocytochrome b558. <i>J Leukoc Biol<\/i>. <b>92<\/b>: 869-882, 2012."},{"key":"12","doi-asserted-by":"publisher","unstructured":"15) Gutierrez, M.G., et al.: Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. <i>Cell<\/i>. <b>119<\/b>: 753-766, 2004.","DOI":"10.1016\/j.cell.2004.11.038"},{"key":"13","unstructured":"16) Gautam, U.S., et al.: Role of TNF in the altered interaction of dormant mycobacterium tuberculosis with host macrophages. <i>PLoS ONE<\/i>. <b>9<\/b>: e95220, 2014."},{"key":"14","unstructured":"17) Wallis, R.S., et al.: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. <i>Clin Infect Dis<\/i>. <b>38<\/b>: 1261-1265, 2004."},{"key":"15","doi-asserted-by":"crossref","unstructured":"18) Ulrichs, T., Kaufmann, S.H.: New insights into the function of granulomas in human tuberculosis. <i>J Pathol<\/i>. <b>208<\/b>: 261-269, 2006.","DOI":"10.1002\/path.1906"},{"key":"16","doi-asserted-by":"crossref","unstructured":"19) Cooper, A.M.: Cell-mediated immune responses in tuberculosis. <i>Annu Rev Immunol<\/i>. <b>27<\/b>: 393-422, 2009.","DOI":"10.1146\/annurev.immunol.021908.132703"},{"key":"17","unstructured":"20) Yasui, K., et al.: Tumor necrosis factor-\u03b1 can induce Langhans-type multinucleated giant cell formation derived from myeloid dendritic cells. <i>Microbiol immunol<\/i>. <b>55<\/b>: 809-816, 2011."},{"key":"18","unstructured":"21) Doran, M.F., et al.: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. <i>Arthritis Rheum<\/i>. <b>46<\/b>: 2287-2297, 2002."},{"key":"19","unstructured":"22) Seong, S.S., et al.: Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. <i>J Rheumatol<\/i>. <b>34<\/b>: 706-711, 2007."},{"key":"20","unstructured":"23) Galloway, J.B., et al.: Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British society for rheumatology biologics register with special emphasis on risks in the elderly. <i>Rheumatology<\/i>. <b>50<\/b>: 124-131, 2011."},{"key":"21","unstructured":"24) Gomez-Reino, J.J., et al.: Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to imcomplete prevention of reactivation of latent infection. <i>Arthritis Rheum<\/i>. <b>57<\/b>: 756-761, 2007."},{"key":"22","doi-asserted-by":"crossref","unstructured":"25) Wallis, R.S.: Tumor necrosis factor antagonists: structure, function, and tuberculosis risks. <i>Lancet Infect Dis<\/i>. <b>8<\/b>: 601-611, 2008.","DOI":"10.1016\/S1473-3099(08)70227-5"},{"key":"23","unstructured":"26) Mohan, V.P., et al.: Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. <i>Infect Immun<\/i>. <b>69<\/b>: 1847-1855, 2001."},{"key":"24","unstructured":"27) Gluck, T., et al.: Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. <i>Arthritis Rheum<\/i>. <b>46<\/b>: 2255-2257, 2002."},{"key":"25","unstructured":"28) Korbel, D.S., et al.: Innate immunity in tuberculosis: myths and truth. <i>Microbes Infect<\/i>. <b>10<\/b>: 995-1004, 2008."},{"key":"26","unstructured":"29) Fucht, D.M., Holland, S.M.: Defective monocyte costimulation for IFN-\u03b3 production in familial disseminated Mycobacterium avium complex infection: Abnormal IL-12 regulation. <i>J Immunol<\/i>. <b>157<\/b>: 411-416, 1996."},{"key":"27","doi-asserted-by":"crossref","unstructured":"30) Rosenzweig, S.D., Holland, S.M.: Defects in the interferon-\u03b3 and interleukin-12 pathways. <i>Immunological Rev<\/i>. <b>203<\/b>: 38-47, 2005.","DOI":"10.1111\/j.0105-2896.2005.00227.x"},{"key":"28","unstructured":"31) Wang, Y., et al.: Protective role of tumor necrosis factor (YNF) receptors in chronic intestinal inflammation: TNFR1 ablation boosts systemic inflammatory response. <i>Lab Invest<\/i>. <b>93<\/b>: 1024-1035, 2013."},{"key":"29","unstructured":"32) Choi, J.P., et al.: An important role of tumor necrosis factor receptor-2 on natural killer T cells on the development of dsRNA-enhanced TH2 cell response to inhaled allergens. <i>Allergy<\/i>. <b>69<\/b>: 186-198, 2014."},{"key":"30","unstructured":"34) Roy, A., et al.: Effect of BCG vaccination against <i>Mycobacterium tuberculosis<\/i> infection in children: systemic review and meta-analysis. <i>Brit Med J<\/i>. <b>349<\/b>: g4643, 2014."}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":["\u7d50\u6838\u514d\u75ab\u304b\u3089\u8003\u3048\u308b\u751f\u7269\u5b66\u7684\u88fd\u5264\u4f7f\u7528\uff0d\u3068\u304f\u306b\u5c0f\u5150\u306b\u304a\u3051\u308b\u7559\u610f\u70b9\uff0d"],"language":"en","deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T03:10:45Z","timestamp":1498187445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/37\/5\/37_423\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.37.423","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}